Compare LOCL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | EQ |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0M | 57.8M |
| IPO Year | N/A | 2018 |
| Metric | LOCL | EQ |
|---|---|---|
| Price | $2.53 | $1.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 17.7K | ★ 510.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,978,000.00 | $4,392,000.00 |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.61 | N/A |
| 52 Week Low | $1.18 | $0.27 |
| 52 Week High | $5.75 | $2.35 |
| Indicator | LOCL | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 56.95 |
| Support Level | $2.48 | $0.84 |
| Resistance Level | $2.70 | $1.44 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 63.64 | 60.99 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.